Silver Book Fact

A medicine is in development that aims to prevent or reverse Alzheimer’s disease progression by using a human monoclonal antibody specifically designed to remove beta amyloid protein from the brain.

PhRMA. 2008 Report: Medicines in Development for Older Americans; November 2008

Reference

Title
2008 Report: Medicines in Development for Older Americans
Publication Date
November 2008
Authors
PhRMA

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • The U.S. Food and Drug Administration has approved 5 drugs that have proven to temporarily slow the worsening of Alzheimer’s disease symptoms for an average of 6 – 12 months…  
  • An Alzheimer’s treatment breakthrough that slowed disease progression and began to show effects in 2015, would reduce Medicaid costs for people with the disease by $62 billion–from the expected $178…  
  • Studies have shown that active medical management of Alzheimer’s disease can significantly improve quality-of-life for the individual through all stages of the disease.  
  • New Medicines in Development for Parkinson’s Disease in 2018
     
  • A current drug in development addresses the underlying cause of type 2 diabetes by modulating genes responsible for insulin sensitization.